Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Peribulbar UC-MSC in Retinitis Pigmentosa
NCT04315025Phase 2Completed
- Sponsor
- Prodia Stem Cell Indonesia
- Start
- Oct 2018
- Primary completion
- Jun 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of human umbilical cord mesenchymal stem cells in retinitis pigmentosa (RP) (3 arms), sponsored by Prodia Stem Cell Indonesia. Primary endpoints: Visual Acuity Test at 3 months, Visual Field Test at 3 months and 5 more. Started Oct 2018; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT04315025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315025.